Actor portrayal.
Fixed treatment periodVENCLEXTA is designed to be completed in a set amount of time (12 months in combination with GAZYVA® [obinutuzumab] for previously untreated CLL/SLL and about 24 months in combination with rituximab for previously treated CLL/SLL), unlike some other oral therapies that you take until your cancer progresses. |
|
Fixed amount of drug exposureBecause the VENCLEXTA regimens are taken for a fixed period of time, there is no additional VENCLEXTA exposure after completing treatment. |
|
Fixed costBecause treatment with VENCLEXTA is completed in a set amount of time, your out-of-pocket costs for the VENCLEXTA regimens are limited to 12 months for previously untreated patients or about 24 months for previously treated patients.* *Coverage may vary by health plan. You may still incur out-of-pocket costs for other treatments or tests as directed by your healthcare provider. |
VENCLEXTA regimens are oral-based, chemo-free treatments for CLL/SLL that you take for 12 months if previously untreated or about 24 months if previously treated. Your healthcare provider will often prescribe VENCLEXTA with an intravenously administered antibody therapy, such as GAZYVA if you are previously untreated or rituximab if you are previously treated, to help you fight CLL or SLL. Your healthcare provider may prescribe VENCLEXTA alone in previously treated CLL/SLL, which is taken until your healthcare provider tells you to stop. |
Always take VENCLEXTA as directed by your healthcare provider.
Actor portrayal.
Learn more about results from the VENCLEXTA clinical trial.
Actor portrayal.
VENCLEXTA can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.
Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.
Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may again check for your risk of TLS and change your dose.
Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS.
Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:
You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.
VENCLEXTA can cause serious side effects, including:
Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.
The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.
VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of VENCLEXTA. For more information, ask your healthcare provider or pharmacist.
You are encouraged to report side effects of prescription drugs to the FDA. Visit
or call 1-800-FDA-1088.
If you cannot afford your medication, contact
for assistance.
US-VENC-200364